Contrast-Enhanced Ultrasound for Kidney Transplant
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Contrast-enhanced ultrasound (CEUS) is a promising non-invasive imaging tool that may aid in
the early detection of kidney transplant complications, such as delayed graft function (DGF)
and acute allograft rejection. The technique uses an intravenous contrast agent to improve
organ visualization with standard duplex ultrasound equipment. A number of FDA-approved
agents, including Optison, Definity and Lumason are widely used to improve visualization in
technically limited echocardiograms, and Lumason was recently approved for contrast-enhanced
ultrasound of the liver. The specific aims of this study are to: develop, implement and
refine a contrast-enhanced ultrasound protocol using Lumason to safely maximize kidney
allograft visualization; determine associations between contrast-enhanced ultrasound and
patterns of allograft injury consistent with delayed graft function; and to compare
contrast-enhanced ultrasound with duplex ultrasound for differentiating acute rejection from
other causes of dysfunction.
Phase:
Phase 1
Details
Lead Sponsor:
Isaac E. Hall
Collaborators:
American Heart Association National Kidney Foundation